Bioreigns

Hallux Inc., based in Laguna Hills, CA, is at the forefront of developing innovative treatments for onychomycosis, specifically through its proprietary Hallux Subungual Gel (HSG). This groundbreaking topical therapy leverages the subungual space to effectively deliver terbinafine directly to the nail bed, offering a promising alternative to traditional oral antifungals. With a focus on safety and effectiveness, Hallux is currently conducting a rigorous phase 2a clinical study to evaluate the efficacy of HSG with hopes of progressing to well-controlled trials leading to FDA approval. By addressing the limitations of existing treatments, Hallux aims to provide a more accessible and affordable option for the millions affected by this common nail disorder. Generated from the website